亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.

杜瓦卢马布 医学 安慰剂 吉西他滨 内科学 危险系数 中期分析 临床终点 临床研究阶段 肿瘤科 癌症 化疗 胃肠病学 外科 临床试验 置信区间 无容量 免疫疗法 病理 替代医学
作者
Do‐Youn Oh,Aiwu Ruth He,Shukui Qin,Li‐Tzong Chen,Takuji Okusaka,Arndt Vogel,Jin Won Kim,Thatthan Suksombooncharoen,Myung Ah Lee,Masayuki Kitano,Howard A. Burris,Mohamed Bouattour,Suebpong Tanasanvimon,Renata Zaucha,Antonio Avallone,Juan Cundom,Nana Rokutanda,Julia Xiong,Gordon Cohen,Juan W. Valle
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (4_suppl): 378-378 被引量:207
标识
DOI:10.1200/jco.2022.40.4_suppl.378
摘要

378 Background: BTC is a rare, heterogenous cancer with poor prognosis. Reports on immunogenic features of BTC suggest checkpoint inhibition may result in antitumor immune responses, and limited clinical activity has been seen with single agents in advanced settings. Durvalumab (PD-L1 inhibitor) + GemCis showed promising antitumor activity in advanced BTC in a phase 2 study. TOPAZ-1 (NCT03875235) is the first global phase 3 study to evaluate first-line immunotherapy + GemCis in advanced BTC. Methods: In this double-blind study, pts previously untreated for unresectable locally advanced, recurrent, or metastatic BTC were randomized 1:1 to receive durvalumab (1500 mg every 3 weeks [Q3W]) or placebo + GemCis (Gem 1000 mg/m 2 and Cis 25 mg/m 2 on Days 1 and 8 Q3W) for up to 8 cycles, followed by durvalumab (1500 mg Q4W) or placebo until disease progression or unacceptable toxicity. Randomization was stratified by disease status (initially unresectable, recurrent) and primary tumor location (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer). The primary objective was to assess overall survival (OS). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and safety. Results: At data cutoff for this interim analysis (11 August 2021), 685 pts were randomized to durvalumab + GemCis (n=341) or placebo + GemCis (n=344; Table). The primary objective was met: durvalumab + GemCis significantly improved OS vs placebo + GemCis (hazard ratio [HR], 0.80; 95% confidence interval [CI], 0.66–0.97; p=0.021). PFS was also significantly improved with durvalumab vs placebo (HR, 0.75; 95% CI, 0.64–0.89; p=0.001). ORR was 26.7% with durvalumab and 18.7% with placebo. Grade 3/4 treatment-related adverse events (TRAEs) occurred in 62.7% of pts receiving durvalumab and 64.9% of pts receiving placebo. TRAEs led to discontinuation of any study medication in 8.9% of pts receiving durvalumab and 11.4% of pts receiving placebo. Conclusions: In pts with advanced BTC, durvalumab + GemCis significantly improved OS and PFS vs placebo + GemCis with manageable safety, indicating durvalumab + GemCis may be a new first-line standard of care regimen. Clinical trial information: NCT03875235. [Table: see text]
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
anugraphics完成签到,获得积分10
2秒前
原神大王的应助被雪山大地采纳,获得10
2秒前
7秒前
7秒前
vfdhjng发布了新的文献求助10
7秒前
完美世界的应助被撩寮采纳,获得10
10秒前
康子浩发布了新的文献求助10
13秒前
多情嫣然完成签到,获得积分10
17秒前
18秒前
ZaZa完成签到,获得积分10
18秒前
21秒前
summerer发布了新的文献求助10
27秒前
Lucas的应助被科研通管家采纳,获得10
28秒前
852的应助被科研通管家采纳,获得10
29秒前
共享精神的应助被科研通管家采纳,获得10
29秒前
殷宵箫发布了新的文献求助10
29秒前
英姑的应助被科研通管家采纳,获得10
29秒前
含蓄的芝麻完成签到,获得积分10
31秒前
ADAB0002完成签到,获得积分10
32秒前
果冻完成签到 ,获得积分10
33秒前
33秒前
vfdhjng完成签到,获得积分20
35秒前
35秒前
可爱的函函的应助被lx采纳,获得10
37秒前
38秒前
华仔的应助被怡宝采纳,获得10
39秒前
summerer发布了新的文献求助20
40秒前
41秒前
嘻嘻哈哈的应助被Gloria采纳,获得10
41秒前
费洛蒙漩涡完成签到,获得积分10
42秒前
孤独孤风完成签到,获得积分10
42秒前
苹果颖完成签到,获得积分10
43秒前
lx完成签到,获得积分10
44秒前
45秒前
45秒前
科研通AI6.4的应助被殷宵箫采纳,获得10
45秒前
46秒前
鱼鱼鱼完成签到,获得积分10
48秒前
lx发布了新的文献求助10
50秒前
50秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165846
求助须知:如何正确求助?哪些是违规求助? 9559318
关于积分的说明 21749858
捐赠科研通 7756681
什么是DOI,文献DOI怎么找? 3429083
关于科研通互助平台的介绍 2553354
邀请新用户注册赠送积分活动 2473622